Sygnature and Heptares in contract chemistry collaboration
Sygnature Chemical Services, a UK provider of chemistry services to the global pharmaceutical industry, and drug discovery company Heptares Therapeutics are to work together to advance one of Heptares" G-protein-coupled receptor (GPCR) programmes.
Sygnature Chemical Services, a UK provider of chemistry services to the global pharmaceutical industry, and drug discovery company Heptares Therapeutics are to work together to advance one of Heptares" G-protein-coupled receptor (GPCR) programmes.
Nottingham-based Sygnature will provide synthetic chemistry services to produce a chemical library for Heptares to evaluate against purified, stabilised and functional proprietary GPCR targets (known as StaRs, stabilised receptors).
"Heptares" decision to work with us demonstrates our growing reputation for delivering "top tier" science coupled with high value and quality," said Dr Simon Hirst, chief executive of Sygnature.
Dr Miles Congreve, head of chemistry at Welwyn Garden City-based Heptares, added: "Sygnature is becoming well known and respected within the pharmaceutical industry for its high-quality medicinal and synthetic chemistry driven services. The company was therefore our choice as a trusted partner to leverage our own internal drug discovery capabilities."
